Expert opinion on investigational drugs最新文献

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma. Isatuximab：一种抗cd38治疗，解决多发性骨髓瘤未满足的需求和耐药机制。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-05-04 DOI: 10.1080/13543784.2026.2660911

Yuxin Liu, Clifton Mo, Shonali Midha, Monique Hartley-Brown, Hans C Lee, Joseph Franz, Omar Nadeem, Taylor Nicholson, Taya Jamal Salman, Anne Fortune, Robert Rifkin, Lauren E Merz, Jesus Berdeja, Jacob Laubach, Peter O'Gorman, Paul G Richardson

{"title":"Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.","authors":"Yuxin Liu, Clifton Mo, Shonali Midha, Monique Hartley-Brown, Hans C Lee, Joseph Franz, Omar Nadeem, Taylor Nicholson, Taya Jamal Salman, Anne Fortune, Robert Rifkin, Lauren E Merz, Jesus Berdeja, Jacob Laubach, Peter O'Gorman, Paul G Richardson","doi":"10.1080/13543784.2026.2660911","DOIUrl":"10.1080/13543784.2026.2660911","url":null,"abstract":"Introduction: In recent years, anti-CD38 antibodies have become integral to the multiple myeloma (MM) treatment armamentarium and greatly improved depth of response and patient outcomes. Isatuximab, an anti-CD38 antibody, is approved for both newly diagnosed MM and relapsed/refractory MM. Understanding the distinct mechanistic features of isatuximab within the anti-CD38 drug class provides further insight into treatment selection.Areas covered: This review discusses the unique mechanism of action of isatuximab, supporting preclinical data, and differentiation from other anti-CD38 antibodies. It will delve into evidence demonstrating the favorable benefit-risk profile of isatuximab in broad patient populations across the MM treatment continuum.Expert opinion: Isatuximab elicits antitumor activity via multiple tumor-targeting pathways. The direct cytotoxic mechanism of isatuximab is a key differentiator from other anti-CD38 antibodies and translates into clinical benefits in patients with MM. Isatuximab only relies partly on complement-dependent cytotoxicity activity for its antitumor activity, which may have beneficial prognostic implications for patients with 1q21 chromosomal abnormalities and extramedullary disease. This is supported by clinical data, which demonstrate a favorable benefit/risk profile in MM patients including difficult-to-treat patients with poor prognostic outcomes. Further, addition of the novel on-body injector to isatuximab administration modalities may provide advantages over current administration methods.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-12"},"PeriodicalIF":4.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative therapies under clinical development for ALS treatment: small molecules. 正在临床开发的治疗ALS的创新疗法：小分子。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-05-03 DOI: 10.1080/13543784.2026.2667249

Loreto Martinez-Gonzalez, Cecilia Sanchez-Santos, Chi-Chen Sarah Huang, Carmen Gil, Ana Martinez

{"title":"Innovative therapies under clinical development for ALS treatment: small molecules.","authors":"Loreto Martinez-Gonzalez, Cecilia Sanchez-Santos, Chi-Chen Sarah Huang, Carmen Gil, Ana Martinez","doi":"10.1080/13543784.2026.2667249","DOIUrl":"10.1080/13543784.2026.2667249","url":null,"abstract":"Introduction: The clinical trial landscape for Amyotrophic Lateral Sclerosis (ALS) is a rapidly evolving field, characterized by significant obstacles but also by an increasing volume of novel therapeutics entering clinical research. Expanding on our 2022 work, this review examines the current state of the ALS clinical pipeline. Given the high volume of ongoing trials, the diversity of their biological targets and the nature of their therapeutic approaches, we focus this comprehensive update in providing a comprehensive overview of the current state of small-molecule development, focusing on agents that have entered or progressed through clinical evaluation since 2022 to the end of 2025.Areas covered: Clinical trials for ALS registered within the United States (ClinicalTrials.gov) and European Union (EU Clinical Trials Register/CTIS) databases have been systematically reviewed and are detailed in this report.Expert opinion: The implementation of advanced clinical trial platforms has introduced more efficient, adaptive strategies, leading to a significant increase in the breadth of explored therapies for ALS. Furthermore, the advent of precision medicine, powered by Artificial Intelligence (AI) for enhanced patient selection and stratification, offers a critical pathway toward overcoming the challenges posed by this severe and heterogeneous disease.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-17"},"PeriodicalIF":4.1,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discontinued therapies for sickle cell disease: status and future directions. 停止治疗镰状细胞病：现状和未来方向。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-23 DOI: 10.1080/13543784.2026.2663116

Akshay Sharma, Shruthi Suryaprakash, Liza-Marie Johnson, Yoram Unguru

{"title":"Discontinued therapies for sickle cell disease: status and future directions.","authors":"Akshay Sharma, Shruthi Suryaprakash, Liza-Marie Johnson, Yoram Unguru","doi":"10.1080/13543784.2026.2663116","DOIUrl":"10.1080/13543784.2026.2663116","url":null,"abstract":"Introduction: Over the past decade, the therapeutic landscape for sickle cell disease (SCD) has expanded beyond hydroxyurea to targeted small molecules, monoclonal antibodies, and transformative cellular and gene therapies. However, not every investigational approach survives the rigor of randomized trials, post-marketing surveillance, and commercial realities. High-profile discontinuations and trial failures have important implications for a disease community with longstanding unmet needs and a historical mistrust of biomedical research.Areas covered: This review analyzes the proximate causes of discontinuation of SCD therapies, highlighting recurrent themes such as overreliance on surrogate endpoints, trial design limitations, post-marketing safety surveillance gaps, enrollment challenges, and corporate reprioritization, and draws lessons for future drug development. We place the most consequential cases in context and discuss how next-generation agents, trial design innovations, biomarker-based strategies, and equitable deployment might reduce the likelihood and impact of future discontinuations. Finally, we propose pragmatic recommendations to maximize patient benefit while minimizing avoidable harms.Expert opinion: Recent advances in sickle cell therapies bring real promise alongside setbacks. Failures are part of progress, but better trial design, transparency, patient partnership, and shared data can reduce harm, strengthen trust, and ensure innovation translates into meaningful, durable patient benefit.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-9"},"PeriodicalIF":4.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: what's new for investigational agents? 靶向非霍奇金淋巴瘤的皮肤t细胞淋巴瘤：研究药物有什么新进展？

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-21 DOI: 10.1080/13543784.2026.2660920

Neha Akkad, Auris Huen, Swaminathan P Iyer

{"title":"Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: what's new for investigational agents?","authors":"Neha Akkad, Auris Huen, Swaminathan P Iyer","doi":"10.1080/13543784.2026.2660920","DOIUrl":"10.1080/13543784.2026.2660920","url":null,"abstract":"Introduction: Cutaneous T-cell lymphomas (CTCLs) are a rare group of T-cell lymphomas originating from skin-homing T-lymphocytes. While patients with early-stage disease may have an indolent disease course and excellent survival rates, patients with advanced-stage disease and the aggressive leukemic variant Sézary syndrome (SS) have poor outcomes with poor responses to therapy and short durations of response. New and better treatments are urgently needed for these patients.Areas covered: This review describes the current treatment landscape including underlying disease biology, diagnosis and staging, approaches to therapy with novel FDA-approved agents including brentuximab vedotin, mogamulizumab, and denileukin diftitiox-cdxl. Novel and upcoming biomarkers, drugs, and therapeutic strategies are additionally covered in detail with a focus on safety, efficacy, and compartment-specific effects.Expert opinion: Recent years have seen a shift away from chemotherapy with the approval of targeted therapies like mogamulizumab, brentuximab vedotin, and denileukin diftitox-cxdl. Though these novel agents have improved outcomes for patients with advanced-stage CTCL, most patients will continue to experience relapses. Emerging agents, including lacutamab, resminostat, and immune checkpoint inhibitors and biomarkers including CD5, CD70, and CD47/Sirpα represent the next frontier in maintaining durable remissions and improving quality of life (QoL) for these patients.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-14"},"PeriodicalIF":4.1,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tafoxiparin effects on cervical ripening and labour augmentation. 他福昔帕林对宫颈成熟和产程的影响。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-20 DOI: 10.1080/13543784.2026.2662357

Valentina Tosto, Carolina Scala, Ambrogio Pietro Londero, Federico Prefumo

{"title":"Tafoxiparin effects on cervical ripening and labour augmentation.","authors":"Valentina Tosto, Carolina Scala, Ambrogio Pietro Londero, Federico Prefumo","doi":"10.1080/13543784.2026.2662357","DOIUrl":"https://doi.org/10.1080/13543784.2026.2662357","url":null,"abstract":"Introduction: . Delayed onset and/or protracted labor progression is a relatively common obstetrical condition. The hypothesis that low molecular weight heparins may induce positive effects on uterine tissues in promoting and shortening delivery time was advanced in the last few years through several retrospective studies in pregnant women treated for thrombotic disorders. Tafoxiparin, a depolymerized form of heparin with a molecular structure created to eliminate the anticoagulant effects of heparins, is under investigation as potential tool to promote labor activation and progression.Areas covered: The authors conducted a critical review on current pharmacological and clinical evidence of tafoxiparin effects on labor.Expert opinion: To date available results may indicate potential benefits of using tafoxiparin for cervical ripening and labor augmentation, but several aspects need further clarifications and investigations. Clinical evidence is still weak to generalize the results of the trials and support the introduction of the drug into daily medical practice, because few studies specifically focussing on this topic were published until now. In addition, many queries are left to be explored with future research, including optimal timing and doses, better route of administration, patient and physician acceptability, target pregnant populations and cost-effectiveness aspects.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ANGPTL3 gene editing with CRISPR-Cas9: early trial insights. 用CRISPR-Cas9编辑ANGPTL3基因：早期试验见解

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-13 DOI: 10.1080/13543784.2026.2656431

Xuan L Tang, Amanda J Hooper, John R Burnett

引用次数: 0

Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics. 微管蛋白聚合抑制剂在早期临床研究中作为癌症治疗药物。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-01 Epub Date: 2026-03-10 DOI: 10.1080/13543784.2026.2640986

Ahmed Kamal, Rahaman Shaik, Prasanna Anjaneyulu Yakkalaa

{"title":"Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics.","authors":"Ahmed Kamal, Rahaman Shaik, Prasanna Anjaneyulu Yakkalaa","doi":"10.1080/13543784.2026.2640986","DOIUrl":"10.1080/13543784.2026.2640986","url":null,"abstract":"Introduction: Microtubules are essential to cancer therapy as key cytoskeletal components that regulate cell division, intracellular transport, and mitotic spindle formation. Tubulin polymerization inhibition is a critical target in anticancer drug development. This review evaluates tubulin polymerization inhibitors (TPIs) in early clinical stages. Using pertinent keywords on tubulin polymerization inhibitors and related trials, literature from January 2018 to January 2026 was obtained from PubMed, Scopus, Embase, Web of Science, ClinicalTrials.gov, and Google Scholar.Area covered: TPIs are classified by their tubulin binding sites into colchicine, vinca alkaloid, and taxane categories. Preclinical data demonstrate strong antiproliferative activity, tumor regression in models, and synergism with DNA-damaging agents, targeted therapies, and immunotherapy. Clinical investigations assess efficacy, identify dose-limiting toxicities, and guide biomarker-based patient selection. Challenges such as drug resistance and pharmacokinetics are addressed through nanoparticle delivery and combination strategies.Expert opinion: TPIs are evolving from traditional cytotoxic agents to precision medicines that exploit molecular differences between cancerous and normal tissues. Advances such as βIII-tubulin as a predictive biomarker enable personalized therapy. Despite challenges, integrating nanotechnology and immunotherapy offers transformative potential. TPIs are emerging as potent agents in precision oncology with enhanced efficacy and reduced toxicity, marking a pivotal shift in targeted cancer treatment.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"273-294"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma. 局部金丝桃素：早期皮肤t细胞淋巴瘤的一种有前途的光动力疗法。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-01 Epub Date: 2026-03-19 DOI: 10.1080/13543784.2026.2643305

James R Poligone, Priyanka Kadam, Elaine S Gilmore, Brian Poligone

{"title":"Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma.","authors":"James R Poligone, Priyanka Kadam, Elaine S Gilmore, Brian Poligone","doi":"10.1080/13543784.2026.2643305","DOIUrl":"10.1080/13543784.2026.2643305","url":null,"abstract":"Introduction: Effective skin-directed therapies (SDT) are the cornerstone for managing early-stage Cutaneous T-cell Lymphoma (CTCL). However, standard treatments like PUVA phototherapy and topical mechlorethamine carry significant drawbacks, including mutagenic risk and treatment-limiting skin reactions. This unmet need has driven demand for safer options. Topical photodynamic therapy with synthetic hypericin (research name: SGX301; trade name: HyBryte™) has emerged as a novel agent addressing this gap.Areas covered: This review details synthetic hypericin's evolution and its unique non-mutagenic, light-activated mechanism. It generates singlet oxygen, preferentially inducing apoptosis in malignant T-cells. We analyze key clinical trials, including the pivotal Phase III FLASH study, to establish its efficacy and safety in patch- and plaque-stage mycosis fungoides, comparing it to other SDTs.Expert opinion: Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"257-263"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma. 靶向CD47/SIRP在癌症中的相互作用：非霍奇金淋巴瘤的机会。

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-01 Epub Date: 2026-03-18 DOI: 10.1080/13543784.2026.2643307

Carlota Pagès-Geli, Kipp Weiskopf

{"title":"Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma.","authors":"Carlota Pagès-Geli, Kipp Weiskopf","doi":"10.1080/13543784.2026.2643307","DOIUrl":"10.1080/13543784.2026.2643307","url":null,"abstract":"Introduction: Macrophages are attractive targets for novel cancer immunotherapy approaches since they can infiltrate into the tumor microenvironment and have the capacity to engulf and destroy cancer cells by phagocytosis. The CD47/SIRPα axis is a key immune checkpoint that regulates macrophages' ability to attack cancer cells and has been the subject of intense preclinical and clinical investigation.Areas covered: We review the scientific rationale for developing CD47/SIRPα-targeting therapies, and we summarize results of recent clinical trials that tested anti-CD47 antibodies, SIRPα-Fc fusion proteins, or anti-SIRPα antibodies in patients with lymphoma. We review signs of efficacy, opportunities for combination strategies, and challenges such as on-target hematologic toxicity and an 'antigen sink' that exists due to CD47 expression on blood cells.Expert opinion: Multiple CD47/SIRPα-targeting therapeutics and multiple clinical trials have demonstrated encouraging results in patients with non-Hodgkin lymphoma, where objective responses have been observed in combination with rituximab and other anti-cancer agents. Next-generation approaches, such as bispecific antibodies and engineering efforts to reduce blood cell binding, are now under clinical development and may be successful strategies to unlock the extraordinary potential of the CD47/SIRPα immune checkpoint.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"265-272"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? 实验性JAK抑制剂：移植物抗宿主病管理的现状、现状和未来？

IF 4.1 2区医学

Expert opinion on investigational drugs Pub Date : 2026-04-01 Epub Date: 2026-03-12 DOI: 10.1080/13543784.2026.2643317

M Abdullah Jamil, Salman Otoukesh, Haris Ali

{"title":"Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?","authors":"M Abdullah Jamil, Salman Otoukesh, Haris Ali","doi":"10.1080/13543784.2026.2643317","DOIUrl":"10.1080/13543784.2026.2643317","url":null,"abstract":"Introduction: Graft-versus-host disease (GVHD) remains the primary barrier to successful allogeneic hematopoietic cell transplantation, contributing significantly to non-relapse mortality. With approximately 50% of patients developing GVHD despite prophylaxis, there is an urgent need for effective alternatives. Janus kinase (JAK) inhibitors have emerged as a promising class of targeted immunomodulators to address this clinical challenge.Areas covered: This review examines the mechanistic rationale for JAK inhibition in GVHD and summarizes key preclinical and clinical data. We evaluate the efficacy and safety of selective and nonselective agents, including ruxolitinib, baricitinib, itacitinib, pacritinib, and rovadicitinib. Furthermore, the review analyzes recent advancements in peri-transplant prophylaxis, biomarker-driven strategies, and the comparative landscape of FDA-approved therapies for acute and chronic GVHD.Expert opinion: The future of GVHD management is shifting from broad immunosuppression toward precision medicine. We anticipate a transition from the current 'steroid-first' paradigm to risk-stratified algorithms utilizing biomarker profiling and novel combination strategies. While ruxolitinib is the current cornerstone, the development of highly selective inhibitors and the resolution of financial access barriers will be crucial for establishing JAK inhibitors as the frontline standard of care over the next decade.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"295-301"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0